Abstract:Nuclear receptors retinoic X receptor α (RXRα) and peroxisome proliferator activated receptor γ (PPARγ) function potently in metabolic diseases, and are both important targets for anti-diabetic drugs. Coactivation of RXRα and PPARγ is believed to synergize their effects on glucose and lipid metabolism. Here we identify the natural product magnolol as a dual agonist targeting both RXRα and PPARγ. Magnolol was previously reported to enhance adipocyte differentiation and glucose uptake, ameliorate blood glucose level and prevent development of diabetic nephropathy. Although magnolol can bind and activate both of these two nuclear receptors, the transactivation assays indicate that magnolol exhibits biased agonism on the transcription of PPAR-response element (PPRE) mediated by RXRα:PPARγ heterodimer, instead of RXR-response element (RXRE) mediated by RXRα:RXRα homodimer. To further elucidate the molecular basis for magnolol agonism, we determine both the co-crystal structures of RXRα and PPARγ ligand-binding domains (LBDs) with magnolol. Structural analyses reveal that magnolol adopts its two 5-allyl-2-hydroxyphenyl moieties occupying the acidic and hydrophobic cavities of RXRα L-shaped ligand-binding pocket, respectively. While, two magnolol molecules cooperatively accommodate into PPARγ Y-shaped ligand-binding pocket. Based on these two complex structures, the key interactions for magnolol activating RXRα and PPARγ are determined. As the first report on the dual agonist targeting RXRα and PPARγ with receptor-ligand complex structures, our results are thus expected to help inspect the potential pharmacological mechanism for magnolol functions, and supply useful hits for nuclear receptor multi-target ligand design.

A review of the molecular design and biological activities of RXR agonists

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

Retinoid X receptor ligands: a patent review (2007 – 2013)

RXR Signaling Targeted Cancer Therapy

The multi-faceted role of retinoid X receptor in cardiovascular diseases

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective

Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases

Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ

Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies

Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor ?t (ROR?t) inverse agonists for autoimmune diseases

Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases

Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents